| Name | Grade | Attribution |
|---|---|---|
| Eribulin, neutropenic sepsis | 4 | Definite |
| Eribulin, neutropenic sepsis | 4 | Definite |
| Eribulin, neutropenic sepsis | 4 | Definite |
| Eribulin, neutropenia | 3 | Definite |
| Eribulin, neutropenia | 3 | Definite |
| Eribulin, neutropenia | 3 | Definite |
| Eribulin, neutropenia | 3 | Definite |
| Eribulin, neutropenia | 3 | Definite |
| Paclitaxel, neutropenia | 3 | Definite |
| Paclitaxel, neutropenia | 3 | Definite |
| Paclitaxel, neutropenia | 3 | Definite |
| Eribulin, fatigue | 3 | Probable |
| Paclitaxel, fatigue | 3 | Probable |
| Paclitaxel, fatigue | 3 | Probable |
| Eribulin, AST abnormality | 3 | Probable |
| Eribulin, ALT abnormality | 3 | Probable |
| Eribulin, dizziness | 3 | Probable |
| Paclitaxel, LVEF abnormality | 3 | Probable |
| Eribulin, myalgia | 3 | Definite |
| Paclitaxel, nasal congestion | 3 | Probable |
| Paclitaxel, nausea | 3 | Probable |
| Eribulin, neutropenic sepsis and death | 5 | Probable |
| Paclitaxel, paresthesia | 3 | Probable |
| Eribulin, vomiting | 3 | Probable |
| Eribulin, white blood cell decreased | 4 | Definite |
If patients received at least one dose of study drug, they were deemed to be evaluable for toxicity. Adverse events including laboratory results were graded according to the National Cancer Institute's CTCAE, version 4.0. Dose‐limiting toxicity was defined as occurrence of adverse events that were attributed as possibly, probably, or definitely related to each study drug and occurring within 2 cycles after the first dose: grade 4 thrombocytopenia or grade 4 neutropenia lasting >1 week or any febrile neutropenia; greater than grade 3 nonhematologic toxic effect; or > 14 days of treatment delay due to any grade of therapy‐related toxic effects (grade 1–2). For patients with multiple instances of the same adverse event and different grades at different instances, we counted the adverse event only once and assigned the highest grade experienced for that event. Toxicity was evaluated on days 8 and 15 for the first 2 cycles and at the end of each cycle thereafter. Dose modification followed standard care for each taxol and eribulin per U.S. Food and Drug Administration package insert and left up to the treating physician's discretion.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; LVEF, left ventricular ejection fraction.